Press releases

Merger agreement to combine the two companies, creating one of the largest medical technology companies in the world

Study was presented at the Association for Vascular Access (AVA) Annual Conference in Savannah, GA

(January 5, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that President and Chief Executive Officer Jim Tobin has agreed to a request from the Board of Directors to extend...

New device pass-through code is only intended for use in the hospital outpatient setting under Medicare

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the year and fourth quarter ended December 31, 2005.

BEACH trial evaluated the benefits of carotid artery stenting (CAS) in conjunction with embolic protection for the treatment of carotid artery disease.

Boston Scientific Corporation (NYSE: BSX) today announced financial results for its third quarter ended September 30, 2005. Read the highlights.

(October 10, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company

New facility includes research and development labs, the Cardiovascular Technology and Product Development organization and other supporting functions.

New complex will serve as the new headquarters for the Company.

The twins took part in a groundbreaking study investigating the effectiveness of bilateral implants as a treatment for deafness in young children.

Award recognizes Company's successful efforts to increase efficiencies in the global supply chain.

"We are pleased with the second quarter results, which featured double digit growth on a global basis," said Jim Tobin, President and CEO.

Precision system is an implantable neurostimulator that masks pain signals.

Innovation represents the latest in treating brain aneurysm

A live webcast and replay of the Tuesday, July 19 session will be available. Learn how to tune in.

Johnson & Johnson's devices found to have infringed two Company patents

(June 27, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling worldwide all Hemashield® VANTAGE™ Vascular Grafts, which are used in peripheral...

(June 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement agreement with the U.S. Department of Justice regarding the Department's...

(June 21, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that a jury in a patent infringement case in U.S. District Court in Delaware brought by Johnson & Johnson (NYSE: JNJ)...

OLYMPIA registry plans to enroll more than 30,000 patients at more than 600 centers around the world.

Company completes final phase; Rubicon now a wholly-owned subsidiary.

A live webcast and replay of the Wednesday, June 15 session will be available. Learn how to tune in.

Dutch court rules that a subsidiary of Johnson & Johnson infringed a Boston Scientific balloon catheter patent.

Quinn will be responsible for Company-wide human resources efforts, supporting all businesses, regions and functions.

The Company announced the estimates at a meeting of financial analysts held in conjunction with the Paris Course on Revascularization (EuroPCR).

TAXUS V trial is studying the most challenging lesions and highest-risk patients ever studied in a randomized, controlled clinical trial in the United States.

Thirty-day safety data reported from global ATLAS clinical trial.

Clinical findings announced at the annual Paris Course on Revascularization.

Two-year follow-up data from TAXUS VI clinical trial consistent with results for slow-release TAXUS formulation.

Results presented are among the most comprehensive intravascular ultrasound (IVUS) follow-up data of any drug-eluting stent randomized clinical trial.

Research may signal new hope for the estimated 18.8 million Americans suffering from depression and four million from AD.

Extended expiration date applies to all sizes of the TAXUS system for sale in the United States.

The Paris Course on Revascularization (EuroPCR) runs from May 24 to 27; read the schedule highlights.

Results were presented in oral and poster sessions at the Digestive Disease Week (DDW) 2005 conference.

A live webcast and replay of the Tuesday, May 17 session will be available. Learn how to tune into the presentation.

A live webcast and replay of the May 3 conference session will be available. Learn how to tune in for the presentation.

BEACH study evaluates the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease.

April 19 edition of JACC is a special issue devoted to the TAXUS IV trial.

"This was another record quarter, thanks in large part to the ongoing success of TAXUS," said Jim Tobin, President and CEO.

Acquisition would bring devices and procedures for treating abdominal aortic aneurysms (AAA).

Company currently distributes CryoVascular's angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries.

NexStent™ recently received CE Mark for commercialization in Europe and certain other international markets.

Facility has received the prestigious NorthFace ScoreBoard Award for excellence in customer service for the second consecutive year.

SYNTAX trial will compare the performance of drug-eluting stents with cardiac surgery in the most complex patient subsets.

Award recognizes Company's accomplishments in creating a project-based system.

(April 7, 2005) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2005 on Tuesday, April 19, at 11:00...

A live webcast and replay of the April 12 conference session will be available.

Launch of Company's three large vessel TAXUS stent systems completes its line of sizes available in Europe and international markets.

With the indication, patients receiving the stent systems may safely undergo Magnetic Resonance Imaging (MRI) examination immediately following implantation.

Precision™ Spinal Cord Stimulation (SCS) System is a powerful new technology that provides many chronic pain sufferers a treatment option that is comfortable, long lasting and effective.

Company no longer markets or sells the NIR stent; findings will not affect Boston Scientific's ability to sell its market-leading TAXUS stent systems.

Company's Quincy Distribution Center approved as a sterilization site for its Cutting Balloon™ microsurgical dilatation device product line.

Company recognized for its achievements in lean manufacturing at its Minnesota facility

A live webcast and replay of the March 15th session will be available. Learn how to tune in.

Trial is designed to analyze "real-world" outcomes for patients with gastroesophageal reflux disease (GERD).

Johnson & Johnson trial results add to the extensive body of clinical evidence reinforcing the safety profile of Company’s TAXUS system.

Nine-month study data presented at the annual American College of Cardiology scientific session in Orlando.

(March 4, 2005) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has completed its acquisition of Advanced Stent Technologies, Inc. (AST) of Pleasanton, California, for an...

(March 3, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the American College of Cardiology annual scientific session, which runs...

TAXUS OLYMPIC registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

Announcement confirms the safety and efficacy of coil embolization for the treatment of ruptured and unruptured brain aneurysms.

A live webcast and replay of the Feb. 8th session will be available. Learn how to tune in for the presentation.

At a meeting with analysts and investors, Company provided ranges for both sales and earnings goals for the three-year period.

Next-generation stent system has been launched in 18 countries.

On February 1, Company will provide financial guidance for 2005, and financial goals for 2006 and 2007. Learn how to tune in.

A live webcast and replay of the January 25th session will be available. Learn how to tune in for the presentation.

Marks a major milestone for the Company and for the treatment of coronary artery disease.

Launch of TAXUS™ Liberté™ paclitaxel-eluting coronary stent system in 18 countries provides physicians state-of-the-art drug-eluting stent technology for the treatment of coronary artery disease.

The announcement was made by Jim Tobin, President and Chief Executive Officer, at the JPMorgan Healthcare Conference in San Francisco.

U.S. District Court in Delaware granted summary judgment of non-infringement in favor of Boston Scientific.

A live webcast and replay of the January 10th session will be available. Learn how to tune in for the presentation.

Jim Tobin, President and CEO, calls Company’s 2004 performance “nothing short of remarkable and speaks to a truly global effort."

Money is being directed to the Red Cross' International Response Fund.

Expansion of management structure is designed to position the Company for continued growth and success.

The transaction is expected to close early next year.

Motions for summary judgment were granted in part and denied in part.

A live webcast and replay of the December 1 conference session will be available.

An existing licensing agreement with Angiotech Pharmaceuticals, Inc. allows Company to obtain an exclusive license for the use of paclitaxel and other agents in the coronary vascular field.

French government adds new patient categories to reimbursement approval criteria.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Equity investment in a privately held company developing a balloon-expandable, bioresorbable drug-eluting stent.

The two series of senior notes will have varied maturities and a combined aggregate principal amount of $500 million.

A live webcast and replay of the November 18 conference session will be available.

Company subsidiary will resume worldwide distribution after a voluntary recall of all unimplanted cochlear implant systems.

TAXUS™ Express2™ paclitaxel-eluting coronary stent system will be the subject of 15 presentations.

A live webcast and replay of the November 10 conference session will be available.

Patients with Gastroesophageal Reflux Disease (GERD) reported substantial improvements after the Enteryx® Procedure.

and Orlando, FL (November 2, 2004)-- Boston Scientific Corporation (NYSE: BSX) today announced results supporting the efficacy of the Enteryx Procedure in relieving the symptoms of...

and Orlando, FL (November 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its ongoing Enteryx Procedure clinical trial for the treatment of...

Innovative uterine fibroid embolization (UFE) procedure is a less-invasive treatment option for fibroids.

Full line of mid-urethral sling products for the treatment of female stress urinary incontinence.

ARRIVE 2 registry program plans to enroll 5,000 patients at approximately 60 centers in the United States.

Repurchased shares will be made available for issuance under the Company's equity incentive plans and for general corporate purposes.

“This quarter was one of the best performances in our history," said Jim Tobin, President and CEO.

Company will launch the product immediately.

A live webcast and replay of the Tuesday, October 19 conference call will be available.

Registries studied more than 7,000 patients at 236 sites around the globe; results consistent with controlled TAXUS studies.

The results support early safety, which is consistent with results from previous TAXUS clinical trials.